Preeclampsia is a disorder of pregnancy characterized clinically by hypertension, proteinuria, and edema and characterized pathologically in its late stages by widespread microvascular thrombi. There is evidence from a number of studies that production of prostacyclin (prostaglandin 12, PGI2), a potent vasodilator and inhibitor of platelet aggregation, is deficient in preeclamptic compared to normal pregnancy. Traditional therapy utilizes infusions of large amounts of MgSO4, but the physiologic basis for this is not clear. We studied the effect of MgSO4 on PGI2 release by cultured human umbilical vein endothelial cells (HUVEC) by several methods. By platelet aggregometry, the known antiaggregatory effect of intact HUVEC was enhanced by MgSO4. By radioimmunoassay for 6-keto-PGFia, the stable metabolite of PGI2, it was shown that MgSO4 amplifies release of PGI2 by HUVEC in a dose-dependent manner, with a peak occurring between 2 and 3 mM. In separate experiments, MgSO4 overcame the enhanced adherence of platelets to HUVEC exhausted by repeated exposure to thrombin. Finally, PGI2 production was 2-to 5-fold greater by HUVEC incubated with plasma obtained from preeclamptic patients undergoing MgSO4 therapy than by HUVEC incubated with pretherapy plasma. We conclude that MgSO4 mediates enhanced production of PGI2 by vascular endothelium, thereby potentially enhancing its thromboresistant properties.
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Preeclampsia is a disorder of pregnancy characterized by hypertension, proteinuria, edema, and, in its advanced forms, coagulopathy and seizures (eclampsia). It is a state of uteroplacental vascular insufficiency with grave prognostic implications for mother and fetus. Preeclampsia occurs with an annual incidence in the United States of 7% (1) , and worldwide it is estimated yearly to cause five million maternal and fetal deaths (2) . In its advanced stages, when biopsied, preeclampsia is characterized pathologically by ballooning of placental and renal endothelial cells and by microvascular occlusions consisting of platelet and fibrin thrombi (3, 4) .
Several lines of experimental evidence suggest that prostaglandin production may be relatively deficient during preeclamptic pregnancy. Levels of prostacyclin (prostaglandin 12, PGI2), a potent inhibitor of platelet aggregation and a vasodilator (5) , are decreased in the urine (6) , amniotic fluid (7) , and trophoblastic tissue (8) in preeclamptic pregnancies compared to levels in fluid and tissue samples obtained from normal pregnancies. Furthermore, umbilical vessels from preeclamptic patients synthesize less PGI2-like activity and convert arachidonic acid to PGI2 at a slower rate than those in normal pregnancy (9) .
That PGI2 deficiency might be critical to the pathogenesis of preeclampsia is a compelling but unproven concept (10) . PGI2 is believed to play an important role in maintenance of thromboresistance at the surface of vascular endothelium by deterring platelet adherence and aggregation (5) , and excessive platelet consumption is a well-described feature of preeclampsia. In fact, preeclamptic patients manifest reduced platelet survival (11) and increased platelet activation, detected by elevated levels of circulating platelet-release products (12) .
Treatment of preeclampsia has not changed significantly in decades: rest, antihypertensive agents, timely delivery, and parenteral MgSO4 (13 (15) . Cells were cultured under 95% air/5% CO2 at 37°C in medium 199 containing 20% fetal bovine serum (GIBCO). They were used at confluence, approximately 5 days after explantation, and were identified as endothelium by their reaction with rabbit antisera to human factor VIII antigen (Boehringer Corporation, New York, NY) (16) .
Preparation of Platelets. Platelets were harvested from citrate (0.36%)-treated venous blood by centrifugation (400 x g for 5 min) to yield platelet-rich plasma (PRP), which was aspirated into plastic tubes and kept at room temperature. Platelet-poor plasma (PPP) was obtained by centrifugation of the remaining blood (1000 x g for 10 min). Platelet counts were adjusted to 300,000 per mm3 by dilution ofPRP with PPP prior to aggregation experiments.
For experiments assessing platelet adherence to cultured endothelium (see below), platelet preparation differed: to wit, platelets were obtained using a modification of the method described by Czervionke et al. (17) . Ten parts venous blood mixed with 1 part acid citrate dextrose (ACD) was centri- PPP, platelet-poor plasma; PRP, platelet-rich plasma.
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fuged (325 x g for 15 min), the resulting PRP was separated by gentle aspiration and recentrifuged (1000 x g for 10 min), and the platelet pellet was resuspended in 10 ml of Tyrode's solution and 0.4 ml of ACD. After the addition of 250 units of heparin and 100 ACi (1 ACi = 37 kBq) of Na25'CrO4 (Amersham), the platelet suspension was incubated at 370C for 20 min. The platelets then were washed four times as described (17) , and the final pellet was suspended in 10 ml of Tyrode's solution to yield =108 platelets per ml. Platelets were used within 4 hr after blood was drawn. PGI2 Determined by Bioassay. We used a bioassay for PG12 that reflects the ability of endothelial cells to inhibit ADP-or epinephrine-induced aggregation of coincubated platelets. For this, we removed HUVEC from culture dishes by trituration after treating them with trypsin/EDTA (3 min, 370C). They were then washed three times in Hepes buffer (5.5 mM dextrose/137 mM NaCl/5 mM KCl/10 mM Hepes/1.8 mM CaCl2, pH 7.35 at 370C) and suspended in PPP. Intact endothelial cells in 50 ,ul of PPP were incubated with PRP (450 ,ul) and normal saline (0.9% NaCl; 50 ,ul) in an aggregation module cuvette (Biodata, Hatsboro, PA) at 37°C, with stirring at 1000 rpm for 5 min. Epinephrine or ADP, freshly diluted in normal saline from stock solutions, then was added in a concentration just sufficient to induce platelet aggregation in the absence of endothelial cells. In some experiments, 50 ,ul of a stock solution of MgSO4 was added to achieve a final concentration of 3 mM. In selected experiments, the endothelial cell suspensions were preincubated with 250 AM aspirin at 37°C for 45 min and then washed three times before coincubation with platelets. Aggregation was measured as percent light transmission over a minimum of 5 min, and inhibition of aggregation by endothelium (a measure of PGI2) was defined as the percent decrease in area under aggregation curves over this time period.
PGI2 Determination by Radioimmunoassay. Cultured HUVEC were incubated with Hepes buffer, as described above, in the presence or absence of 20 ,M sodium arachidonate (Sigma). For some experiments, various concentrations of MgSO4 (1-5 mM) in Hepes buffer were added to the buffer. After incubation for 5 min at 37°C, the cell-free supernatant fluid was aspirated and assayed without extraction for the stable PGI2 metabolite, 6-keto-PGFia, by radioimmunoassay (New England Nuclear). In other experiments, MgSO4 was replaced by MgCl2 (1-5 mM), MnSO4 (1 and 3 mM), or Na2SO4 (1 and 3 mM). Total cellular protein, measured by the method of Lowry et al. (18) with multiple additions of buffer, and the nonadherent fractions were pooled. Adherent platelets and their attached endothelial cells were solubilized with 2% Na2CO3 in 0.1 N NaOH, and their radioactivity, as well as that of the pooled nonadherent fraction, was measured in a gamma scintillation counter. Percent adherence was calculated by dividing adherent cpm by total cpm added per dish and multiplying by 100. Recovery of total radioactivity (adherent plus nonadherent platelets) averaged 90%.
RESULTS

MgSO4
Augments HUVEC Capacity to Inhibit Platelet Aggregation. As reported previously (31), endothelial cells inhibit platelet aggregation induced by epinephrine or ADP. As shown in Table 1 Significantly different from control (P < 0.005, n = 14).
sulfate, is responsible for the increment in PGI2 release, since almost identical results are obtained when MgCl2 is substituted for MgSO4 (Table 2) . Further, neither MnSO4 nor Na2SO4 causes an increase in 6-keto-PGFia release by endothelial cells in the presence or absence of sodium arachidonate (data not shown).
Platelet-Endothelium Adherence. To approximate in vitro the possible effect of MgSO4 on the interactions between platelets and the blood vessel wall in vivo, we assayed the adherence of platelets to HUVEC in culture. Human endothelial cell monolayers rapidly exhaust their ability to release PGI2 when repeatedly stimulated with thrombin (19) . Thus, platelets normally do not avidly adhere (less than 2%, Fig. 2 ) to endothelial cells in culture, presumably because of PGI2 release. Adherence increased significantly (P < 0.005) to 11.1% after one thrombin stimulation and 15.3% after two thrombin stimulations (Fig. 2) , which others (19) have shown is associated with diminution of endothelial cell PGI2 synthesis. The addition of MgSO4 reduces by about half the augmented platelet adherence that follows endothelial exposure to sequential thrombin (Fig. 2) ; that is, from 11.1 to 6.6% Cultured endothelial cells were exposed once or twice to thrombin (1.0 unit/ml, 5 min), or exposed to aspirin (250 AuM, 45 min), in the presence (solid bars) or absence (hatched bars) of 3 mM MgSO4. Adherence of 51Cr-labeled platelets to endothelium was determined by scintillation counting. Data are represented as mean ± SEM (n = 10).
after one stimulation (P < 0.005), and from 15.3 to 8.6% after two stimulations (P < 0.01). Thus, MgSO4 appears to replenish or protect the capacity of endothelium to provide PGI2 activity otherwise exhausted by repeated exposure to thrombin. Its effect is on endothelium and not platelets, as pretreatment of endothelial cells with aspirin, either in the presence or absence of MgSO4, blocks resistance to thrombin (Fig. 2) . Plasmas from MgSO4-Treated Patients Increase PGI2 Release by HUVEC. Plasma obtained from three preeclamptic patients during therapeutic MgSO4 infusions induced a striking release of PGI2 when added to cultured HUVEC (Table  3) . When compared to release induced by autologous pretreatment plasma, the increase in PGI2 release was 2-to 5-fold greater with posttreatment plasma. These increases in PGI2 in vitro occurred at concentrations of magnesium in plasmas (28) . In a recent study presented in abstract form (29) , Mg>2 infusion stimulated urinary PGI2 excretion in vivo. This effect was antagonized by indomethacin and Ca2+-channel blockers, leading the authors to postulate that Mg2> infusion alters cellular Ca> flux and thereby enhances PGI2 release (29) .
Regardless of the mechanism, we note that at least one other disease (thrombotic thrombocytopenic purpura) involving accelerated platelet consumption with microvascular occlusions by platelet aggregates has been postulated to be due to PGI2 deficiency (30) . We suggest that MgSO4 may, therefore, be beneficial to these patients also.
